Spokane, WA, October 6, 2025 — Gestalt is proud to announce the release of PathFlow Version 6, the latest evolution of its award-winning digital pathology platform. This major update introduces a dynamic, high-powered field of view designed to elevate the diagnostic experience for pathologists, along with a dedicated tumor board workflow module that streamlines multidisciplinary collaboration, in addition to other features. PathFlow Version 6 delivers a robust visual interface that enables pathologists to navigate their images with greater precision, speed, and clarity—supporting complex case reviews and high-volume workflows without compromise. The enhanced field of view is optimized for performance across diverse specimen types, and in a manner that is familiar and comfortable to them. By providing pathologists with this embedded high-power field of view, they are able to standardize the quantitative assessment of specific cells or features within a tissue sample, which is essential for cancer diagnosis, tumor grading, and determining patient prognosis, ensuring diagnostic confidence every time. The newly developed tumor board module provides the focused workflow needs for supporting real-time collaboration across oncology teams, radiologists, and pathologists. With configurable workflows, secure data sharing, and the ability for both admins and pathologists to easily add, update and remove cases and images institutions can now conduct tumor board reviews with greater efficiency and clinical alignment. “ This release reflects our commitment to empowering pathologists with tools that not only enhance diagnostic accuracy but also foster meaningful collaboration, ” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “ PathFlow Version 6 is built for the demands of modern pathology and the future of precision medicine. ” PathFlow V.6 is available immediately to existing customers and new partners seeking scalable, interoperable digital pathology solutions. It is being featured during DPA’s Pathology Visions Conference in San Diego this week. Come to booth #600 for a personalized demonstration. Not going to Visions? Reach out for more information. -- About Gestalt Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

Spokane, WA – October 2, 2025 — Gestalt, a leader in digital pathology and AI-driven laboratory solutions, is proud to announce that Tulsa Medical Lab (TML) has selected PathFlow®as their digital pathology solution, marking a major step forward in the lab’s strategy to streamline operations, enhance diagnostic accuracy, and accelerate the adoption of AI-driven workflows. With this partnership, TML aims to unify its diagnostic process across multiple laboratory information systems, enabling pathologists to access all of their cases through a single login and in one consolidated worklist. The implementation of PathFlow will also give TML access to integrated AI tools designed to support efficiency and accuracy throughout the diagnostic process. “ Gestalt is one of the best vendors I've ever worked with in my 20+ years as a pathologist, ” said Dr. Anne V. Herdman Royal, Managing Partner, TML. “ They are honest, clear in delivering on their goals and promises, and they are genuinely interested in improving the ease and efficiency of the pathologist's digital pathology experience. ” Tulsa Medical Lab selected Gestalt for its pathologist-focused approach, robust platform features, and ability to support scalable innovation. The lab’s long-term goal is to create a “one-stop shop” digital-based system that streamlines access to all pathology cases, empowering its team to work more collaboratively and efficiently while laying the foundation for future AI-enabled diagnostic workflows. “ We are proud to partner with Tulsa Medical Lab as they take this important step toward digital transformation ,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “ Their vision for a unified, pathologist-centered digital environment aligns closely with our mission to deliver scalable, interoperable solutions that improve diagnostic efficiency and patient care. ” Through this collaboration, Gestalt continues its commitment to transforming laboratory workflows by providing innovative technology, strategic partnerships, and purpose-driven solutions that advance healthcare outcomes worldwide. About Gestalt Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose diseases faster and more efficiently. Our PathFlowTM solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn About Tulsa Medical Laboratory Tulsa Medical Laboratory is a CAP-accredited, independently owned anatomic pathology group serving physicians, clinics, and hospitals throughout Northeastern Oklahoma. The laboratory provides a comprehensive range of diagnostic services, including histopathologic evaluations, cytology interpretations, bone marrow examinations, clinical consultations, blood bank services, peripheral blood and other body fluid smear consultations, and frozen section evaluations. Dedicated to delivering accurate, timely, and patient-centered care, Tulsa Medical Laboratory combines deep expertise with a commitment to quality, innovation, and collaboration. All of which are advancing the practice of pathology and improving healthcare outcomes for the communities it serves.

The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.

Roslyn Heights, NY, Sept. 11, 2025 -- Voicebrook, Inc., the leading provider of pathology reporting solutions, today announced a new integration with Gestalt Diagnostics, a leader in digital pathology solutions. This partnership represents the industry's first fully speech-enabled digital pathology solution, enabling laboratories to streamline workflows, reduce inefficiencies, and deliver faster, more accurate results for patients. The integration connects Voicebrook’s VoiceOver PRO reporting platform with Gestalt’s PathFlow digital pathology solution, giving pathologists the ability to control both image navigation and report creation entirely by voice. Pathologists can dictate report sections, complete CAP protocols when required, and seamlessly move between reviewing slides and capturing structured data—all without interrupting their diagnostic flow. " Pathologists face increasing demands to work faster without compromising accuracy, " said Melanie Shedd, VP of Product at Voicebrook. " This integration brings together the best of both worlds—Voicebrook’s proven reporting capabilities and Gestalt’s innovative digital pathology platform—so laboratories can deliver high-quality, CAP-compliant reports more efficiently. " With the combined solution, pathology teams benefit from: Seamless Workflo w: Direct integration between digital slide management and reporting. Efficiency Gains : Voice-enabled navigation and data capture reduce manual entry and workflow disruptions. Flexibility : Support for both narrative reporting and CAP protocols, tailored to any lab’s needs. Improved Collaboration : Enhanced ability for pathologists to share insights and finalize cases quickly. " Gestalt’s mission is to empower pathologists through digital innovation, " said Gestalt’s President, Lisa-Jean Clifford. " Our integration with Voicebrook aligns perfectly with that vision—giving labs a solution that is both powerful and easy to use. " The Voicebrook–Gestalt integration is available now, for laboratories seeking to enhance their digital pathology and reporting capabilities. ### About Voicebrook: Founded in 2002, Voicebrook is the leading provider of reporting solutions for pathology, with approximately 3600 users at 500 sites worldwide. The company’s VoiceOver PRO and SynoptIQ software applications allow pathology professionals to rapidly and accurately create pathology reports. VoiceOver PRO incorporates speech recognition, digital dictation, customizable templates, CAP eCP, and an assortment of input devices, providing direct integration with the user’s Anatomic Pathology (AP) system. SynoptIQ is a full-featured eCP solution solely focused on CAP cancer reporting. Learn more at www.voicebrook.com About Gestalt Diagnostics: Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose diseases faster and more efficiently. The company's PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. The platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable expertise where it matters most. To learn more, visit www.gestaltdiagnostics.com

With the focus on digital pathology adoption around the globe today, efficiency and accuracy are an expected advantage for deployments in pathology labs of all sizes and types. With the continued advancement of these technologies, solutions like PathFlow and its lighter version, PathCloud, are revolutionizing the way pathologists manage their workflows. With PathFlow and PathCloud’s robust cloud-based capabilities, you have secure access your cases and images anywhere and anytime. With it truly interoperable infrastructure, PathFlow provides streamlined access, routing, and tools directly within the pathologists workflow. Pathology is becoming more in demand, case loads are increasing, pathologist availability is decreasing and the prediction for the number of new patients being diagnosed are all adding strain to the laboratory and the physicians. With a purpose designed infrastructure, PathFlow is made to decrease the manual workload and increase workflow optimization. PathCloud, the cloud-based lighter application to PathFlow, helps ensure pathologists can have access to tools and data from virtually anywhere on the globe in a cost effective, low footprint entry point to digital pathology. PathCloud’s secure environmen delivers real-time access to high-quality images and your case information. Both applications provide enhanced security and efficiency for your peace of mind.

Featured in Medical Laboratory Observer - MLO Written By Lisa-Jean Clifford, President, Gestalt Planning is Essential As digital pathology and artificial intelligence (AI) continue to transform diagnostic medicine, laboratories find themselves at a timely and critical juncture. These technologies are not simply enhancements, they represent a fundamental shift in how clinical images and data are managed, routed, shared, viewed, interpreted and presented to pathologists. Laboratories that wish to remain at the forefront of innovation must evolve beyond traditional automation and digitally replicating their manual workflows. Instead, the lab who successfully implements these solutions must carefully evaluate its technical infrastructure to accommodate complex, image-centric workflows, multi-source data integration, and AI-assisted analysis. This evolution requires careful analysis and review of platforms that not only handle high-resolution whole slide images (WSIs), but also enable interoperable communication across diverse systems—such as scanners, LIS’s, EMR’s, EHR’s, and archives—using both native file formats and standardized protocols like DICOM. Successful implementation of digital pathology and AI depends upon a robust informatics ecosystem that supports interoperability and real-time data exchange between your applications. These include information that will be displayed in your viewer such as WSI’s, structured annotations, snapshots, AI overlays and results outputs but also includes patient specific case information like you traditionally see in your LIS. These tools must be securely embedded within workflows, ensuring compliance with privacy regulations, while remaining scalable for multi-site deployments. And, this transformation is not solely technical. It requires training and cultivating a digitally fluent workforce, with training initiatives that enable pathologists, lab (and scanning) technicians to navigate the components of the process seamlessly and accurately. Assess current infrastructure preparedness Before implementing new technologies, it’s essential for laboratories to assess their existing systems and infrastructure. This includes evaluating scanner compatibility, data storage capabilities, and network bandwidth to ensure readiness for high-volume imaging, robust case routing and AI integration. Understanding what's already compatible and supports this initiative can help identify gaps, avoid redundant investments, and lay the foundation for seamless upgrades. A thoughtful audit sets the stage for informed decisions and smoother transitions into digital pathology and automation. Key considerations include: Scanner selection – Do you already have scanners in place? If so, are the digital solutions you are evaluating compatible with all of them? Do the scanners fit the needs of your organization in terms of volumes, speed and quality of scanning, redundancy? Are they dated or current in terms of the technology? If they aren’t, or you don’t have scanners these are all items to consider in your evaluation and acquisition of scanners. Keep in mind that the better digital platforms will support multiple scanner brands and models, enabling you to mix and match the scanners that best suit your organizations needs. Information Management System(s) – Is your LIS/EMR/EHR interoperability ready or compatible? Is it an older, legacy system that will have limitations or challenges with being able to send and receive real-time data messages through standard methods of integration? Can your digital solution providers help bridge any of these gaps or do they have ways they can work around them in order to provide a seamless workflow for your pathologists and your technologists? If your information system or “source of truth” for the patient is current and easy to integrate with other solutions, do you have one or multiple you are looking to integrate with? Are you a multi-site entity or single location with one LIS or one version of that LIS? All of these are points to consider when determining: 1. Which digital solution you select; and 2. If there are other infrastructure changes you need to make to ensure that your applications are able to speak to each other effectively. Network Bandwidth – Most robust digital solutions today are web-based, as is the storage for these large images. It is essential to understand what your current network supports and to plan to make modifications prior to implementing a digital platform. Speed and performance are a huge factor in the successful usage and adoption of your platform. Most digital solutions are going to be optimized for performance, but internet and network bandwidth are two things that no vendor can account for. There are certainly things like load balancing and viewer performance that are important parts of the development and tuning process of vendors, however, providing the proper bandwidth and connectivity is something that the lab – or your IT department – will need to plan on. Storage options – Preplanning is an important step here as well. Knowing whether you are going to archive all of your images or some of your images and for what amount of time is a key consideration. Also understanding your options and selecting the one (or two) that are right for you is important. Are you planning to store locally/onsite? In the web? Does your digital solution provider offer both short – and long-term storage? Are you looking to use one of the large storage vendors (Google, AWS, Azure)? Understanding the price difference between these options, and if your digital solution provider can integrate bi-directionally with them is also a fundamental consideration. On this note – any decision you make in this category can be easily changed. Configure for Interoperability A successful digital pathology deployment depends upon integration, real-time data exchange and true interoperability. Support for image formats – Enables streamlined viewing, image sharing and best of breed selection for your organization across platforms. Are you looking to integrate your other ‘ologies’ and have a cross patient perspective by being able to collocate radiology and pathology images? If so, you also need to ensure that your systems support DICOM and integration with VNRs. Open APIs and HL7 – Enable seamless connectivity with LIS, AI algorithms, other lab applications and modules, and advanced analytics platforms Vendor-Neutral solutions – Avoid vendor lock-in by selecting digital platforms that offer interoperable viewers, databases, workflows and reporting. Choose AI vendors and algorithms that align with your needs AI algorithms should be carefully considered and evaluated to ensure that you address your specific clinical needs rather than adopt them as generic tools. Successful integration requires a thoughtful alignment by your digital pathology solution and the AI vendor. Those who have formed partnerships have put a great deal of thought and technical evaluation into the integration between the capabilities of their AI outputs and the digital workflow and visual representation to the pathologist. Whether it's assisting with tumor detection, streamlining case triage, or supporting specific diagnosis and cancer grading, AI solutions should be targeted to enhance clinical workflows and improve decision-making. By integrating AI deployment directly within your digital platform’s viewer, you are enabling your workflow to be grounded in the realities of patient care and operational demands, ensuring that laboratories can have a meaningful impact, increased efficiency, and better outcomes. Modernizing your lab’s infrastructure isn’t a single upgrade—it’s a strategic transformation. By focusing on compatibility, clinical utility, and scalable systems, labs can future-proof their operations and unlock the full potential of digital pathology and AI.

Featured in CAP TODAY Written By Lisa-Jean Clifford, President, Gestalt The length of time to install digital pathology equipment, interface, implement, train, and go live in 10 large laboratories ranged from under one year to about 18 months, and the time spent prior to that—evaluating options, gaining budget approval, making decisions, and completing the contract and negotiation process—took eight months to a year for seven of the 10. For two others, the evaluation, decision-making, and contracting process took about 18 months, and for one it took five years, largely owing to pandemic-related delay. These are some of the findings that came from interviews with 10 of the largest laboratories that have adopted digital pathology in the United States, conducted by Lisa-Jean Clifford, president of Gestalt Diagnostics. She presented her findings at the Executive War College meeting in April. Clifford offered the laboratories the choice to remain unnamed. Of the 10, five agreed to be named: Alverno Laboratories, Intermountain Health, Labcorp, Memorial Sloan Kettering, and Sonic Healthcare. Two laboratories started on their path to digital pathology in 2004 and 2007, and eight started between 2015 and 2019. The aforementioned timelines the labs shared did not include the lengthy time spent before that deciding who among the laboratory staff and leaders would participate in the decision-making and seek approvals, determine what the organizational requirements were, develop the request for proposal, and determine which vendors would participate in the RFP. Several factors explain the variation in the timelines, she said, among them the differing time frames, experience, and ability of the IMS vendors to interface; the availability of LIS, EHR, and other vendors and their resource availability to support the interfacing and implementations; and the number of the lab locations and complexity of the organizations’ workflows and whether the organizations went live with artificial intelligence. The pandemic interrupted the process for two other labs, though they lost less time. Five of the laboratories accelerated their process during the pandemic. The two early adopters reevaluated their solutions and changed vendors when their existing contracts expired. “Both found that early technology was not as interoperable or adaptable to interfacing as they needed them to be,” Clifford said, calling it an artifact of the technology available at the time or attributing it to a lack of understanding of how the digital use cases would evolve once an organization deployed. Most of the 10 labs started with a single type of use case or workflow and then expanded once that use case or workflow had been mastered internally, Clifford said. Noting that IMS vendors vary in the modules or workflows they support, she reported that all 10 labs were using their IMS for clinical workflows. Eight were using their IMS for primary diagnosis and tumor boards, four supported resident workflows, two were for molecular work, and five labs were also using it for research. “Only one was actively using their digital IMS vendor for consults,” Clifford said. “Ninety percent were performing consults manually or outside their LIS and IMS.” The current state of digital pathology adoption in these 10 labs is not where any of them plan to remain, she said. Three of the labs did not disclose their percentage of adoption and case volumes; one lab disclosed that it is at 80 percent adoption but did not share its case volume. Of the six labs that disclosed case volumes and percentage of adoption, the three with the largest case volumes were at less than 10 percent of overall adoption. “The three laboratories with the overall lowest case volumes were at the highest rate of adoption,” Clifford said, “with one at 80 percent and two at 100 percent.” Among the barriers to adoption the labs cited, IT was the biggest, with all 10 labs saying “they had issues in their IT processes for one reason or another,” Clifford said. Slide quality was another barrier, with the problems being the quality of the glass slides or of the scans. Cost was a third barrier, though it was not the cost of the IMS, she said, but of “the scanners and image storage for the organizations that wanted access to the stored images indefinitely.” Two of the labs that cited pathologist resistance as a barrier said some of the resistance was a belief that the digital workflow was slowing pathologists down. One of the labs did an internal study in which they showed that by going digital, in three to six months (four months on average), “pathologists were faster on digital than on glass,” Clifford said. All 10 labs said they realized benefits from adopting digital pathology, and the benefit-related categories were rated at high levels in terms of their realization. They are better patient care, turnaround time, specialty routing, no shipping of glass, workload balancing, and being able to instantly move cases to where the capacity is. AI is the only benefit category that was rated as a low realization, “not reflected in the perceived value of the benefit,” Clifford said, “but in the number of laboratories that had adopted AI,” which was half (with four using it for primary diagnosis). Of those that had not yet adopted AI, she said, “they understand this is the future, and they recognize that this is the way the industry is moving. They’re just not there yet.”

By Maarion Napora At Gestalt, we understand the role of education for physicians and why it is important to have a focus specifically on pathology. It is our goal to provide the proper digital tools and platforms for pathologists to learn how to use the latest technology in their training. PathFlow ’ s Education Module provides academic medical centers and residency programs with leading tools and digital technology to train the next generation of pathologists. Designed to meet the demands of modern techniques, the module offers the ability to develop courses, easily clone and copy courses, and assign teaching lists, images, and tests. You can set the timing for a course, automatically send out messages to remind students of outstanding courses and test deadlines, etc. We support multiple forms of media, including videos, PowerPoint presentations, and word documents. These enable educators to deliver immersive, digital-first learning experiences. The PathFlow Education Module Revolutionizes pathology training by providing a unified platform for interactive learning. Trainees can access a comprehensive library of annotated digital slides, practice diagnosing complex cases, and receive real-time feedback. Professors can easily grade, provide comments and feedback on assessments, and can even assign certificates. The module’s credentialing management capabilities streamline competency assessments, notifications for deadlines, and reminders if not completed, ensuring residents meet rigorous standards while tracking progress seamlessly. We believe education and access to leading technology is the cornerstone of advancing pathology. With PathFlow’s Education Module, we’re empowering academic programs to train confident, tech-savvy pathologists, who will lead the field forward with current skills in available technology informatics.

Spokane, Washington, July 9, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, showcased its AI-powered pathology platform, PathFlow, at the Spring 2025 DICOM WG-26 Interoperability Connectathon, confirming its readiness for real-world clinical integration and multi-vendor environments. The Connectathon was co-sponsored by the Digital Pathology Association (DPA) and the European Society of Digital and Integrative Pathology (ESDIP). The event, hosted virtually from January to June and featured at the European Congress on Digital Pathology in Barcelona, brought together over 30 organizations to validate end-to-end workflows, in varying categories, using DICOM standards. The categories included image acquisition, storage, viewing, and AI-driven annotations. Gestalt’s platform stood out as a leader in interoperability, particularly as an Image Display (Viewer). Gestalt’s Viewer successfully displayed images from 8 of 9 different WSI Scanners, demonstrating seamless compatibility with multiple diverse systems such as 3DHISTECH, Grundium, Leica, Hamamatsu and Pramana. This robust performance ensures pathologists can access high-quality whole slide images effortlessly, regardless of the source, streamlining diagnostic workflows. Additionally, PathFlow excelled in displaying annotations from five AI Evidence Creators, including industry leaders like Visiopharm, Hologic, TechCyte and identify.bio, further demonstrating its ability to present structured data for precise diagnostic insights. As an Evidence Creator itself, (AI Annotations), Gestalt showcased its advanced AI capabilities, by analyzing and annotating images from eight scanners. These annotations were successfully transmitted to five different image management archives using standard DICOM Web protocols, highlighting Gestalt’s ability to deliver accurate, standards-compliant AI-driven outputs. This functionality empowers pathologists to integrate AI seamlessly into routine clinical operations, improving efficiency and diagnostic accuracy. “Gestalt’s performance at the Connectathon reflects our dedication to building interoperable, scalable solutions that empower pathologists globally,” said Brian Napora, VP of Innovation, Gestalt Diagnostics. “By investing in open standards, we’re helping lead digital pathology toward a more integrated and intelligent future.” The Connectathon’s rigorous testing environment validated Gestalt’s ability to handle real-world challenges, such as legacy image integration and complex multi-vendor workflows without requiring custom workarounds. Gestalt’s commitment to DICOM standards positions PathFlow as a cornerstone for vendor-neutral, future-ready pathology solutions. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn